Cassava Sciences, Inc. (PX91.F)
- Previous Close
19.57 - Open
20.61 - Bid 19.88 x --
- Ask 20.05 x --
- Day's Range
20.61 - 20.61 - 52 Week Range
11.50 - 27.80 - Volume
451 - Avg. Volume
140 - Market Cap (intraday)
997.167M - Beta (5Y Monthly) -0.37
- PE Ratio (TTM)
-- - EPS (TTM)
-2.12 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
159.25
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
www.cassavasciences.comRecent News: PX91.F
Performance Overview: PX91.F
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PX91.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PX91.F
Valuation Measures
Market Cap
976.69M
Enterprise Value
864.85M
Trailing P/E
--
Forward P/E
18.98
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
13.63
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.23%
Return on Equity (ttm)
-33.90%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-47.9M
Diluted EPS (ttm)
-2.12
Balance Sheet and Cash Flow
Total Cash (mrq)
124.17M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
6.44M